α-syn

TCH-165 is a small molecule modulator of proteasome assembly, resulting in an increase in 20S levels. The increase in the level of free 20S corresponds to enhanced proteolysis of IDPs.

α-syn aggregation inhibitor-1 (Compound 2e) acts as an inhibitor of α-syn aggregation. It is capable of inhibiting the cell viability of SH-SY5Y.

2N4R Tau/α-Syn against-1 (Compound 4d) targets α-synuclein and tau proteins, inhibiting the fibrillization and oligomerization of these proteins, and displays depolymerization activity against Aβ fibers. 2N4R Tau/α-Syn against-1 is applicable in Parkinson's and Alzheimer's disease research.

tau Protein/α-synuclein-IN-2 (Compound 14T) is a tau and α-synuclein inhibitor capable of crossing the blood-brain barrier. It reduces α-synuclein oligomerization in a dose-dependent manner through a thiourea linker structure. In biosensor cells, tau Protein/α-synuclein-IN-2 prevents tau aggregation seed effects. In the M17D neuroblastoma model, this compound exhibits anti-inclusion effects and reduces Aβ plaque formation. tau Protein/α-synuclein-IN-2 shows potential for Alzheimer's and Parkinson's disease research.

α-Synucleininhibitor 10 inhibits α-Syn aggregation activity with a low IC50 value of 1.08 μM and demonstrates strong binding affinity to α-Syn residues. It is applicable for research on Parkinson's disease (PD).

α-Synucleininhibitor 11 (compound 1) is a selective inhibitor of α-synuclein (α-syn) oligomer formation. It does not inhibit tau 4R (isoforms 0N4R, 2N4R) or p-tau (isoform 1N4R). α-Synucleininhibitor 11 can be utilized for Parkinson's disease (PD) research.

α-Synuclein inhibitor 12 (compound 4ce) is an inhibitor of α-Syn (α-synuclein) aggregation, suitable for research in neurological disorders.

α-Synucleininhibitor 13 is an inhibitor of α-synuclein (α-Syn). It can prevent the aggregation of α-Syn protein and disassemble already formed fibrils, primarily used in Parkinson's disease research.

α-Synuclein inhibitor 3 (Compound 7g) is a potent inhibitor of α-synuclein (α-Syn) aggregation, with potential applications in Parkinson's disease research [1].

α-Synuclein inhibitor 6 (compound 3ge) is a blood-brain barrier-permeable agent that effectively inhibits α-Synuclein (α-Syn) aggregation, demonstrating a potent IC50 value of 1.70 μM and achieving an inhibition ratio of 94.4% at 30 μM [1].

α- Synuclein inhibitor 7 (compound 3gf) is effective α- Synuclein ( α- Syn) aggregation inhibitor, IC50 is 1.95 μM, inhibition rate at 30μM was 85.8%. α- Synuclein inhibitor 7 has blood-brain barrier permeability.

α-Synuclein inhibitor 5 is a potent inhibitor of α-Synuclein (α-Syn) aggregation across the blood-brain barrier (IC50: 1.22 μM), with 94.3% inhibition at 30 μM.

α-Synuclein inhibitor 9 (Compound 20C) targets and binds to cavities within mature α-synuclein fibrils, diminishing their β-sheet content. It effectively inhibits the aggregation of A53T α-synuclein, exhibits neuroprotective properties, enhances brain functionality, and alleviates motor impairments. This compound is utilized in research related to Parkinson's disease (PD). [1]

Tau protein/α-synuclein-IN-1 is a dual inhibitor that not only impedes tau protein and α-synuclein but also reduces the development of α-syn inclusions in M17D neuroblastoma cells, making it a useful agent in the study of Alzheimer's disease [1].

α-Synucleinmodulator 1 (Compound 7k) acts as a modulator of α-synuclein. In an ACN/PBS (1:1) buffer solution, it exhibits maximum absorption and emission wavelengths at 386 nm and 603 nm, respectively.

PROTACα-synuclein degrader 6 (compound T3) is a PROTAC degrader of α-synuclein and tau, with an EC50 of 1.57 μM and 4.09 μM, respectively. This compound plays a significant role in neurodegenerative disease (ND) research.

α-Synuclein (61-75) is a peptide fragment derived from the larger protein α-Synuclein, which is predominantly found in presynaptic nerve terminals and considered a biomarker candidate for Parkinson's disease (PD).

α-Synuclein inhibitor 4 (compound 3gh) is a highly effective, blood-brain barrier-permeable inhibitor of α-Synuclein aggregation, demonstrating potent activity with an IC50 value of 0.98 μM and an inhibition ratio of 91.2% at 30 μM [1].

Dyrk1A/α-synuclein-IN-1 (Compound b1) is a dual inhibitor of Dyrk1A (IC50: 177 nM) and α-synuclein aggregation (IC50: 10.5 μM), characterized by CNS permeability and neuroprotective activity.

Dyrk1A/α-synuclein-IN-2 (Compound b20) is a dual inhibitor of Dyrk1A and α-synuclein aggregation with an IC50 of 7.8 μM for α-synuclein. It exhibits high predictive CNS permeability and has a neuroprotective effect.

α-Synuclein inhibitor 8 effectively impedes α-Synuclein aggregation and disaggregation with an IC50 of 2.5 µM, demonstrating substantial reduction in neuronal inclusion formation, which contributes to reparative effects in damaged neurons and symptomatic improvement in Parkinson's disease (PD)-like models. The compound also exhibits high antioxidant activity and low cytotoxicity [1].

α-Synuclein (61-75) TFA is a fragment (residues 61-75) of the predominantly presynaptic neuronal protein α-Synuclein, serving as a potential biomarker for Parkinson's disease (PD) [1] [2].

PROTAC α-synuclein degrader 3 (compound 5) is a potent and selective agent for degrading α-synuclein, used in Parkinson's disease research [1].